Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Medullary 1

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × yeast-CEA vaccine × Clear all
NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

ImmunityBio, Inc.

Phase 1/2 Terminated
9 enrolled 18 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡